For the quarter ended June 2025, Ultragenyx (RARE) reported revenue of $166.5 million, up 13.2% over the same period last year. EPS came in at -$1.17, compared to -$1.52 in the year-ago quarter.
The reported revenue represents a surprise of +2.94% over the Zacks Consensus Estimate of $161.74 million. With the consensus EPS estimate being -$1.27, the EPS surprise was +7.87%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ultragenyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales- Dojolvi: $23.21 million versus $22.38 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +19.9% change.
- Revenues- Product sales- Evkeeza: $14.57 million versus $11.08 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +85.5% change.
- Revenues- Product sales- Mepsevii: $8.31 million versus the eight-analyst average estimate of $8.64 million.
- Revenues- Total Crysvita revenue: $120.41 million versus the seven-analyst average estimate of $118.04 million.
- Revenues- Product sales: $80.82 million versus $84.66 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
- Revenues- Royalty revenue: $85.68 million versus $77.43 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +17% change.
View all Key Company Metrics for Ultragenyx here>>>
Shares of Ultragenyx have returned -28.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
